Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.

Dreyling, Martin ; Jurczak, Wojciech ; Jerkeman, Mats LU ; Silva, Rodrigo Santucci ; Rusconi, Chiara ; Trneny, Marek ; Offner, Fritz ; Caballero, Dolores ; Joao, Cristina and Witzens-Harig, Mathias , et al. (2016) In The Lancet 387(10020). p.770-778
Abstract
Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the efficacy and safety of ibrutinib versus temsirolimus in relapsed or refractory mantle-cell lymphoma.
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
The Lancet
volume
387
issue
10020
pages
770 - 778
publisher
Elsevier
external identifiers
  • pmid:26673811
  • scopus:84959074796
  • wos:000370418000036
ISSN
1474-547X
DOI
10.1016/S0140-6736(15)00667-4
language
English
LU publication?
yes
id
510f4b65-b6b9-4a3c-b3ad-77ea36e877ed (old id 8504580)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26673811?dopt=Abstract
date added to LUP
2016-04-04 08:25:34
date last changed
2022-04-23 17:11:05
@article{510f4b65-b6b9-4a3c-b3ad-77ea36e877ed,
  abstract     = {{Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the efficacy and safety of ibrutinib versus temsirolimus in relapsed or refractory mantle-cell lymphoma.}},
  author       = {{Dreyling, Martin and Jurczak, Wojciech and Jerkeman, Mats and Silva, Rodrigo Santucci and Rusconi, Chiara and Trneny, Marek and Offner, Fritz and Caballero, Dolores and Joao, Cristina and Witzens-Harig, Mathias and Hess, Georg and Bence-Bruckler, Isabelle and Cho, Seok-Goo and Bothos, John and Goldberg, Jenna D and Enny, Christopher and Traina, Shana and Balasubramanian, Sriram and Bandyopadhyay, Nibedita and Sun, Steven and Vermeulen, Jessica and Rizo, Aleksandra and Rule, Simon}},
  issn         = {{1474-547X}},
  language     = {{eng}},
  number       = {{10020}},
  pages        = {{770--778}},
  publisher    = {{Elsevier}},
  series       = {{The Lancet}},
  title        = {{Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.}},
  url          = {{http://dx.doi.org/10.1016/S0140-6736(15)00667-4}},
  doi          = {{10.1016/S0140-6736(15)00667-4}},
  volume       = {{387}},
  year         = {{2016}},
}